Biomedical sciences research infrastructures

BioMedBridges forms a cluster of the emerging biomedical sciences research infrastructures (BMS RIs) and construct the data and service bridges needed to connect  them.

  • The BMS RIs are on the roadmap of the European Strategy Forum on Research Infrastructures (ESFRI)
  • The missions of the BMS RIs stretch from structural biology of specific biomolecules to clinical trials on thousands of human patients
  • Most serve a specific part of the vast biological and medical research community, estimated to be at least two million scientists in Europe across more than 1000 institutions from more than 36 ESFRI Member States and Associated Countries
  • Each of them brings together its own large community of users to build a coordinated infrastructure. This process has already had a major impact on coordination of national infrastructures within each member state
  • Essentially all BMS RIs are distributed infrastructures, with nodes in many European member states
  • All BMS RIs will support world class biological and medical research and further our understanding of biological processes.  The information they will generate will advance the state of the art and will contribute to our growing understanding of biological processes

The outcomes of BioMedBridges will lead to real and sustained improvement in the services the biomedical sciences research infrastructures offer to the research community. Data curation and sample description will be improved in all of them by the adoption of best practices and agreed standards. Many improvements will emerge from new interactions between RIs created by data linkage and networking.

The main benefit of integration however comes to all the infrastructures and all of Europe’s scientists. By creating an environment that allows data and service exchange in the biological and medical sciences, we will empower scientific research and its translation into industry, the clinic and the environment, to address the grand challenges Europe faces in the 21st century.

BBMRI logo

BBMRI—Modern clinical research will be significantly supported by linking large collections of high quality, well documented samples from humans and model organisms. By integrating data from biobanks and molecular research, and by improving access to metadata, the descriptions and therefore discoverability of biomedical samples will be hugely improved.

 EATRIS logo EATRIS—In personalised medicine, decisions about treatment options will be supported by access to integrated data and information from multiple reference resources and analysis platforms.
 ECRIN logo ECRIN—Data relevant to personalised medicine that is generated by the different research infrastructures will be made available to scientists and clinicians in an ethical, robust and sustainable manner, and mechanisms of interoperability for different data types will be developed. Clinical trial data, biomolecular data and basic research data will be better linked.
 ELIXIR logo ELIXIR—New discoveries will be facilitated by revealing possible connections between linked and accessible biomolecular, clinical, biobank (tissue sample) and image data.

Infrafrontier—The mouse is an important model organism for studying human disease. Harmonising ontological descriptions of phenotype in mouse and human and improving links between mouse model data and human data, using diabetes and obesity as examples, will increase the relevance of data that is generated in mouse studies for clinical studies.

 INSTRUCT logo Instruct—Structural data on biomolecules will be linked with clinical data, maximising its value by enabling its use in studies of important biological and medical problems.
 ERINHA logo ERINHA—Strains of known species and unknown species of pathogens will be more easily distinguished and accurately identified by linking to biomolecular data. This is important in controlling epidemics and in security applications.
 EU-OPENSCREEN logo EU-OPENSCREEN—The enormous effort involved in high throughput screening for chemical tools and drugs will be supported by building targeted strategies based on integrated clinical, cheminformatic, and biomolecular data.
 EMBRC logo EMBRC—Links to metagenomics data will help characterise poorly understood ecosystems and cheminformatics data to characterise the activity of isolated natural products.

Euro-BioImaging—Extensive image data sets representing different biological scales spanning biomolecules, cells, tissues and organisms will be linked, enabling drug-target and biomarker discovery for human disease.

Associate Partners


ISBEIn tackling complex biological problems, ISBE will enable European scientists to implement research from a systems perspective. Through strengthening Europe’s economic and scientific competitiveness, ISBE will also improve the quality of life for EU citizens.  In addition, industry will be offered the best training, collaborations, services and development of technologies. 


MIRRIA Pan-European distributed research infrastructure that provides microorganisms services facilitating access to high quality microorganisms, their derivatives and associated data for research, development and application.